ReviewCancer genetics
Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma.
Review in Cancer genetics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma.Blood cancer journal · 2019Review
- Immunosenescence and lymphomagenesis.Immunity & ageing : I & A · 2018Review
- A novel approach for medical research on lymphomas: A study validation of claims-based algorithms to identify incident cases.Medicine · 2018Article
- CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial.Haematologica · 2017Article
- Rituximab-Based Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: Individualized Risk-Adapted Therapy Approach Using Molecular Subtypes.Journal of hematology · 2017Review
- Article
- 25 Years Old Women With Inflammatory Low Back Pain.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2016Article
- FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.Leukemia · 2016Article
- Precision medicine in diffuse large B-cell lymphoma: hitting the target.Haematologica · 2015Article
- IL-17 induces radiation resistance of B lymphoma cells by suppressing p53 expression and thereby inhibiting irradiation-triggered apoptosis.Cellular & molecular immunology · 2015Article
- Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network.British journal of cancer · 2015Article
- Polymorphism in interleukin 21 gene is associated with decreased susceptibility to diffuse large B cell lymphoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Tim-3 expression is increased on peripheral T cells from diffuse large B cell lymphoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.European urology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The rapid emergence of molecularly based techniques to detect changes in the genetic landscape of diffuse large B cell lymphoma (DLBCL), including gene expression, DNA and RNA sequencing, and epigenetic profiling, has significantly influenced the understanding and therapeutic targeting of DLBCL. In this review, we briefly discuss the new methods used in the study of DLBCL. We describe the influence of the generated data on DLBCL classification and the identification of new entities and altered cell survival strategies, with a focus on the renewed interest in some classic oncogenic pathways that are currently targeted for new therapy. Finally, we examine the molecular genomic studies that revealed the importance of the tumor microenvironment in the pathogenesis of DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.